Applicant, as named in the Orange Book

Onyx Pharms Amgen

Amgen Inc · Nasdaq: AMGN

Company and ticker: cliffwatch mapping, checked against SEC EDGAR · SEC filings

Next listed expiry: Kyprolis on 29 Oct 2041. 1 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	Earliest generic entry	Basis
Kyprolis NDA 202714 · 3 strengths carfilzomib	carfilzomib	29 Oct 2041 patent	patent

Kyprolis · Generic tentatively approved · ANDA 219276, Hainan Poly Pharm. Co., Ltd.Tentative approval 7 Nov 2025Detected 25 Oct 2026
Kyprolis · Generic approved · ANDA 209526, MsnApproved 20 Jul 2026Detected 25 Oct 2026